Kevin Weinstein joined SPH Analytics in 2020 as President of the Population Health business unit. Prior to joining SPH Analytics, Kevin served as the Chief Growth Officer of Apervita, whose platform allowed payers and providers to collaborate for more efficient quality measurement and value-based contracting. Before that, Kevin was the CEO of Analyte Health, a pioneering company empowering consumers to live healthier lives by making health and diagnostic lab tests directly accessible to consumers. Kevin successfully turned around the company operationally and successfully sold the company. Immediately prior to Analyte Health, Kevin was the Chief Growth Officer at Valence Health, where he oversaw the company’s growth from $30 million to $140 million in revenue in four years, until the company’s successful sale to Evolent Health (NYSE: EVH). Previously, Kevin was recruited to start the marketing department at ZirMed, a leading revenue cycle management technology company for healthcare providers backed by Sequoia Capital. Kevin started his healthcare career as Vice President of Marketing and Sales Operations at Allscripts, a leading provider of clinical software, connectivity, and information solutions for healthcare providers. During his time at Allscripts, Kevin and his team helped more than double sales to over $140 million, and had the #1 ranked product in KLAS. Earlier in his career, Kevin worked in both management consulting and venture capital. Kevin received his MBA from Northwestern’s Kellogg School of Management and a BA in English from Colgate University.